The Centers for Medicare & Medicaid Services today  it will update the hospital outpatient prospective payment system rates by 1.35% in calendar year 2018 compared to CY 2017. The rule also finalizes CMS鈥檚 proposal to drastically cut Medicare payment for drugs that are acquired under the 340B Drug Pricing Program. Specifically, CMS will pay separately payable, non pass-through drugs (other than vaccines) purchased through the 340B program at a rate of the average sales price minus 22.5%, rather than ASP plus 6%. Sole community hospitals in rural areas, PPS-exempt cancer hospitals and children鈥檚 hospitals will be excepted from this policy for CY 2018. CMS is implementing this policy in a budget neutral manner by offsetting the estimated $1.6 billion in reductions in drug payments by redistributing that amount to other non-drug services within the OPPS. 鈥淐MS鈥檚 decision in today鈥檚 rule to cut Medicare payments to hospitals for drugs covered under the 340B program will dramatically threaten access to health care for many patients, including uninsured and other vulnerable populations,鈥 said AHA Executive Vice President Tom Nickels. 鈥溾e strongly urge CMS to abandon its misguided 340B rule, and instead take direct action to halt the unchecked, unsustainable increases in the cost of drugs. In the meantime, the AHA will work with Congress to address this issue. In addition, the AHA will be joining the Association of American Medical Colleges, America鈥檚 Essential Hospitals and our members to pursue litigation to prevent these significant cuts to payments for 340B drugs from moving forward.鈥 Among other changes, the OPPS final rule reinstates for CYs 2018 and 2019 the moratorium on enforcement of the direct supervision policy for outpatient therapeutic services for critical access hospitals and small rural hospitals with 100 or fewer beds. In addition, CMS is removing total knee arthroplasty from the inpatient only list. Further, the agency delays implementation of the outpatient and Ambulatory Surgery Center Consumer Assessment of Healthcare Providers and Systems survey-based measures in the Outpatient Quality Reporting program until further notice. The rule also removes six quality measures from the OQR program. AHA members will receive a Special Bulletin with further details tomorrow. The CY 2018 physician fee schedule final rule, which will contain final site-neutral policies under Section 603 of the Bipartisan Budget Act of 2015, is expected to be released later this week.

Related News Articles

Headline
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a report detailing findings from an investigation鈥
Headline
The AHA April 18 filed friend-of-the-court briefs in three cases in support of Louisiana's 340B contract pharmacy law that prohibits drug companies from鈥
Headline
A Minnesota state court April 15 dismissed a lawsuit filed by PhRMA challenging the state鈥檚 law protecting 340B pricing for contract pharmacy arrangements. The鈥
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription鈥
Headline
The Department of Health and Human Services said its decision to prevent drug companies from implementing a 340B rebate model 鈥渨as within its statutory鈥
Headline
The AHA this week filed a number of friend-of-the-court briefs in cases before the U.S. District Court for the District of Columbia, urging the court to uphold鈥